GlassScriptPhysician profile
Jacqueline D Watchmaker
NPI 1033568761
$123,264.74
in general payments reported to CMS, 2019-2025
27 companies · $34K in 2025
The $34K reported for 2025 was more than what 95% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $773 · 2020: $350 · 2021: $491 · 2022: $2,647 · 2023: $27K · 2024: $58K · 2025: $34K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $70K · Consulting Fee: $31K · Food and Beverage: $10K · Travel and Lodging: $7,546 · Education: $96.55.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $70,350.00 |
| Consulting Fee | $30,641.64 |
| Food and Beverage | $10,368.68 |
| Travel and Lodging | $7,545.87 |
| Education | $96.55 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $99,669.26 | 2019-2025 | Botox, Kybella |
| Merz North America, INC. | $14,721.76 | 2024 | |
| Botanix Sb INC | $2,205.98 | 2025 | Sofdra |
| Dermavant Sciences, INC. | $998.15 | 2023-2024 | Vtama |
| Allergan, INC. | $888.02 | 2019-2022 | |
| Verrica Pharmaceuticals INC. | $822.42 | 2023-2025 | Ycanth |
| Galderma Laboratories, L.P. | $786.48 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $471.55 | 2021-2025 | |
| Genzyme Corporation | $415.28 | 2019-2025 | |
| Amgen INC. | $376.61 | 2021-2025 | Otezla, Otezla |
| Janssen Biotech, INC. | $367.10 | 2019-2024 | Tremfya |
| Biofrontera INC. | $330.07 | 2022-2023 | Ameluz, Xepi, Bf-Rhodoled |
| Celgene Corporation | $216.55 | 2019 | |
| Lilly USA, LLC | $164.43 | 2020-2025 | Taltz, Ebglyss, Olumiant |
| Regeneron Healthcare Solutions, INC. | $151.11 | 2022-2025 | Libtayo, Dupixent |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Revance Therapeutics, INC. | $101.83 | 2024-2025 | Daxxify |
| Organogenesis INC. | $82.46 | 2019 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $74.27 | 2020-2021 | |
| Novartis Pharmaceuticals Corporation | $73.73 | 2021-2025 | |
| Incyte Corporation | $63.80 | 2025 | Opzelura |
| Solta Medical, A Division of Bausch Health US, LLC | $62.58 | 2025 | Clear+Brilliant |
| Organon LLC | $53.12 | 2025 | Vtama |
| Arcutis Biotherapeutics, INC. | $48.50 | 2023-2024 | Zoryve |
| Ucb, INC. | $42.78 | 2025 | Bimzelx |
| Almirall LLC | $35.13 | 2023 | Klisyri, Seysara |
| Leo Pharma INC. | $26.38 | 2025 | Anzupgo |
| Helsinn Therapeutics (U.S.), INC. | $15.39 | 2025 | Valchlor |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jacqueline Watchmaker listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.